Effort #9009 to discredit anything and everything about CCSI, by those who really wish to destroy the company. It is beyond me why the attack persists, and words are twisted. Efforts to discredit anyone and everyone connected with CCSI is getting very old.
Last week thestreet.com threw out the stock genie, and CCSI was to have paid them for coverage. This week the stock genie does not exist, and cannot be contacted. A PO Box in Long Island. thestreet.com put that at the end of the article.
>>In addition, the attempts of Whistleblower to find Magic Moe also failed to turn up anything. Stock Genie did not respond to an inquiry emailed to the address on its site. A search into the Internic Web directory turned up a post office box in Port Washington, N.Y., but according to the phone company, there is no such listing in that town. A lawyer on Long Island contacted by Whistleblower said he had done some legal work for Stock Genie, adding he would forward our request and have them contact us.
We're still waiting. >>
From thestreet.com Dr Maisels made his points, after words were twisted.
Maisels told TSC, "Anybody in the medical field would agree, you want to test further. I don't know whether that would be before using it, but further tests are being done."
Here's the kicker: "I would collect data, personally, before using it," he said. "The fact that it's FDA approved doesn't mean it's proven. CCSI is doing tests to confirm its reliability. Do I believe it works? From the data I've seen, yes. But it's only one study."
What doctor would not want to test and know as much about any new product before using, particluraly one which might have a serious result for an infant?
isels is a paid consultant to Chromatics who said he has received "on the order" of several thousand dollars from the company, but less than $5,000. He said he owns no stock or options in the company. Maisels is on the company's advisory board. In an interview today, Chromatics CEO Darby Macfarlane said Maisels had received $5,900 since 1997 for setting up the protocol on the multisite trial and also received traveling expenses.
A paid tout, no a doctor is reimbursed for travel expenses and all expenses in setting up a clinical site. These were expense, not salary.
Macfarlane said, "What's he's talking about is that the company is in the midst of multicenter trials. For the ultimate acceptance of the product, for the pinnacle, you always do multicenter trials." She said multicenter trials are done in medical devices and are "not required. But they are respected by the medical community. It makes the marketing effort easier."
"They are solely for marketing purposes to the medical community," Macfarlane went on. "It's the same thing other medical devices do. I'm not a medical company here. I'm learning from my distributors," whom she said told her this type of trial would be required for market penetration. She said that the company is conducting a trial at Parkland Hospital in Dallas that will probably end in August. The company, along with its potential distributors, will decide on other hospitals to add to the study.
fternoon, Maisels and Macfarlane called back for a conference call. During that call, Maisels clarified his earlier statements. He said of Colormate, "I think it is safe and efficacious as a bilirubin monitor," adding, "depending on the circumstances, you could use Colormate and not a blood test."
When asked why his afternoon statement appeared different from the morning's, he said, "The company has not told me to say something different. I want to make sure I say what I meant to say. What you read to me is essentially correct. I don't want to back off that statement. This is the normal way to test for this kind of technology.
"This will be used as an adjunct to heel sticks. I am confident that it will replace the overwhelming majority of heel sticks."
OVERWHELMING IS THE KEY WORD HERE.
Maisels stood by his critique of short-seller Asensio's reports on Chromatics. The doctor said, "The statements he made were incorrect, were false." He adds, "I never said in the statement that I was willing to use it. I simply responded to Asensio's statement, which had numerous inaccuracies." The inaccuracies were enumerated in the June 11 press release.
"WERE FALSE" WERE THE KEY WORDS IN THAT STATEMENT. ASENSIO'S STATEMENTS WERE FALSE!
Maisels said of Asensio, "He doesn't know what he's talking about. It was necessary to respond because as it is, it adds up to a misleading picture."
"HE DOESN'T KNOW WHAT HE'S TALKING ABOUT" ARE THE KEY WORDS HERE.
aisels said, "In my view, the availability of a noninvasive system for [infant jaundice] measurement would be a tremendous boon." Is Colormate it? In the morning interview he said, "I think it has the potential for being it."
READ AND REREAD THIS ABOVE STATEMENT.
------------------------------------------------------------------------
What about CCSI's rebuttal about its hanging around with Magic Moe?
Macfarlane stated in the press release: "Chromatics has had no contact with Stock Genie, nor have we paid or authorized any payment for any profile which may have been posted on their site."
As Whistleblower stated last week, Stock Genie's most recent profile, emailed June 13, highlighted several past "successful" picks the Genie had made. Among them it mentions Chromatics, referring to a July 1997 profile it said it had done on the company. Stock Genie states on its site that it receives a fee in cash and/or stock from most of the companies it profiles; the site also stipulates that "all information is provided by the companies profiled."
However, Macfarlane told TSC in a separate interview yesterday that she had "never heard of the Stock Genie." She also says that an internal investigation did not find any record of payment to Stock Genie. The timing of the profile dovetails with approval the company received from the FDA, Macfarlane said.
"It would have had to come across my desk," she said. While she conceded the possibility that an outside interested party could have paid for the profile, she is not aware of any such arrangement.
Chromatics put out the press release to quell shareholders' concerns over the company's involvement with Stock Genie, Macfarlane said, adding that Chromatics' efforts to locate Stock Genie and find the source of this profile has been so far unsuccessful.
In addition, the attempts of Whistleblower to find Magic Moe also failed to turn up anything. Stock Genie did not respond to an inquiry emailed to the address on its site. A search into the Internic Web directory turned up a post office box in Port Washington, N.Y., but according to the phone company, there is no such listing in that town. A lawyer on Long Island contacted by Whistleblower said he had done some legal work for Stock Genie, adding he would forward our request and have them contact us.
We're still waiting. <Picture>
<Picture>
|
